Gland Pharma Ltd (GLAND) Q3FY25 Concall Summary - Dec-2024 Qtr
Performance Overview
- Gland Pharma reported consolidated Q3 FY25 revenue of INR 13,841 million and EBITDA of INR 3,600 million, representing a 26% EBITDA margin, a 100 bps year-on-year increase.
- Base business (excluding Cenexi) revenue declined 8% year-on-year to INR 10,123 million due to volume degrowth in key products, partially offset by new launches.
- Base business EBITDA margin improved significantly to 39% compared to 34% in Q3 FY24, driven by product mix changes and cost optimization measures.
- Thirteen new molecules were launched in the US market during the quarter, including Chlorpromazine, Dexamethasone, Phenylephrine, Phytonadione, and Diphenhydramine.
- Rest of the World markets contributed 21% to the total revenue in Q3 FY25.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.